Research Analysts Issue Forecasts for RVMD Q3 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities research analysts at Brookline Capital Markets issued their Q3 2026 earnings per share (EPS) estimates for shares of Revolution Medicines in a report released on Thursday, October 15th. Brookline Capital Markets analyst L. Cann expects that the company will post earnings of ($2.36) per share for the quarter. Brookline Capital Markets currently has a “Buy” rating and a $318.00 target price on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.93) per share. Brookline Capital Markets also issued estimates for Revolution Medicines’ Q4 2026 earnings at ($1.94) EPS.

A number of other analysts have also recently issued reports on the company. Raymond James Financial reissued a “strong-buy” rating and set a $248.00 price objective on shares of Revolution Medicines in a report on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday. Evercore restated an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. UBS Group upped their target price on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Finally, Truist Financial lifted their price target on Revolution Medicines from $240.00 to $241.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Moderate Buy” and an average target price of $242.60.

Revolution Medicines Trading Up 2.4%

Shares of NASDAQ:RVMD opened at $182.15 on Tuesday. The company has a 50-day moving average price of $202.72 and a two-hundred day moving average price of $174.59. Revolution Medicines has a twelve month low of $52.48 and a twelve month high of $224.31. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the company earned ($1.31) EPS.

Insider Buying and Selling

In related news, insider Mark Goldsmith sold 80,000 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the sale, the insider directly owned 267,330 shares in the company, valued at $55,925,436. This represents a 23.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Elizabeth Anderson sold 10,143 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the sale, the director directly owned 4,333 shares in the company, valued at approximately $836,442.32. This trade represents a 70.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 290,991 shares of company stock valued at $59,422,765 over the last quarter. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds have recently made changes to their positions in the business. SteelPeak Wealth LLC purchased a new stake in shares of Revolution Medicines during the third quarter valued at $1,520,000. IFP Advisors Inc raised its holdings in shares of Revolution Medicines by 8.7% during the third quarter. IFP Advisors Inc now owns 810 shares of the company’s stock valued at $166,000 after purchasing an additional 65 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Revolution Medicines in the third quarter worth approximately $810,000. TD Waterhouse Canada Inc. raised its stake in Revolution Medicines by 37.0% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 370 shares of the company’s stock valued at $76,000 after buying an additional 100 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Revolution Medicines by 987.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after buying an additional 1,980,699 shares during the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.